Unum Therapeutics Inc. (UMRX) financial statements (2021 and earlier)

Company profile

Business Address 200 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2423756
Cash and cash equivalents2423756
Receivables 22
Other undisclosed current assets3124
Total current assets:2454181
Noncurrent Assets
Operating lease, right-of-use asset55
Property, plant and equipment023
Restricted cash and investments111
Other noncurrent assets 00
Total noncurrent assets:695
TOTAL ASSETS:2514986
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:575
Accounts payable132
Accrued liabilities112
Employee-related liabilities132
Other undisclosed accounts payable and accrued liabilities210
Deferred revenue 1
Debt 2 
Contract with customer, liability18
Other undisclosed current liabilities832
Total current liabilities:131325
Noncurrent Liabilities
Long-term debt and lease obligation34 
Operating lease, liability34
Liabilities, other than long-term debt  1
Deferred rent credit  1
Other undisclosed noncurrent liabilities(3)  
Total noncurrent liabilities:341
Total liabilities:161826
Stockholders' equity
Stockholders' equity attributable to parent, including:2353260
Common stock000
Additional paid in capital322156152
Accumulated other comprehensive loss  (0)
Accumulated deficit(199)(124)(92)
Other undisclosed stockholders' equity attributable to parent111  
Total stockholders' equity:2353260
TOTAL LIABILITIES AND EQUITY:2514986

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues82210
Cost of revenue(50)  
Gross profit:(42)2210
Operating expenses(41)(55)(46)
Operating loss:(82)(32)(36)
Nonoperating income701
Investment income, nonoperating001
Other nonoperating income100
Net loss attributable to parent:(75)(32)(35)
Preferred stock dividends and other adjustments  (0)
Other undisclosed net loss available to common stockholders, basic(104)  
Net loss available to common stockholders, diluted:(179)(32)(35)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(75)(32)(35)
Other comprehensive income 00
Comprehensive loss, net of tax, attributable to parent:(75)(32)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: